Lyell Immunopharma

Lyell Immunopharma is a clinical-stage biotechnology company specializing in next-generation CAR T-cell therapies for cancer patients. The company is dedicated to advancing innovative treatments that aim to provide durable tumor cytotoxicity and achieve consistent, long-lasting clinical responses. Founded by pioneers in cell therapy, Lyell has built a fully integrated organization capable of discovering new technologies, translating science into therapies, manufacturing cell therapy products, and clinically evaluating them in patients. The company's culture is based on Science, Respect, Collaboration, and Courage, reflecting its commitment to innovation and patient care.